Comparative Pharmacology
Head-to-head clinical analysis: X TROZINE L A versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: X TROZINE L A versus XYZAL.
X-TROZINE L.A. vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
5 mg orally once daily in the evening.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine